||||||||||ADX-324 / ADARx HAE Prophylaxis by Targeting Prekallikrein With siRNA- Phase 1 Interim Safety Outcomes and Prekallikrein Levels (Monitor 12) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_876; P1 Conclusion The interim outcomes provide preliminary evidence that ADX-324 is safe and significantly decreases PKK levels for at least 3 months. This should translate to effective prevention of HAE attacks with convenient long intervals between doses.